Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-743921 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SB-743921 | DRUG | - |
Inclusion criteria: * Histologically or cytologically confirmed diagnosis of: a) Advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy; OR b) B-cell or T-cell lymphoma (excluding HIV-associated lymphoma) that has relapsed or is refrac...
SB-743921 is an investigational small molecule being studied for the treatment of solid tumor cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy in patients.
SB-743921 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the drug's potential in oncology.
SB-743921 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied for the treatment of solid tumor cancer. The Phase 1 trial has been completed, and the drug remains under investigation.
SB-743921 has been studied in one clinical trial, identified as NCT00136513, titled "SB-743921 In Patients With Solid Tumors." This Phase 1 trial was completed in the United States and enrolled 30 adult patients with solid tumor cancer.
SB-743921 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for solid tumor cancer. The completed Phase 1 trial, NCT00136513, was an uncontrolled study, and the drug has not yet received regulatory approval.